Study Suggests SGLT2 Inhibitors Provide Benefits for Very Elderly Adults with Chronic Kidney Disease

New real-world data presented at Kidney Week, the annual meeting of the American Society of Nephrology held in Denver, indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors may offer substantial clinical benefits for adults aged 80 years and older who live with chronic kidney disease (CKD). While older individuals often face complex health challenges, recent findings highlight how targeted medical therapies could improve outcomes in this underrepresented population.

Examining the Real-World Data on SGLT2 Inhibitors

Led by Dr. Julian Doricic from Medizinische Hochschule Hannover in Germany alongside colleagues, the study analyzed the effects of SGLT2 inhibitor therapy among elderly patients. To conduct the analysis, researchers utilized the TriNetX database to identify 23,765 SGLT2 inhibitor users and nonusers who were at least 80 years old. The research team applied propensity score-matching to account for various comorbidities, laboratory parameters, and frailty-associated factors between the groups.

Following a two-year follow-up period, the investigators observed a significant reduction in mortality among patients who received SGLT2 inhibitors. The adjusted hazard ratio for mortality was calculated at 0.734, with researchers noting that a similar mortality benefit appeared consistently across all predefined subgroups. Additionally, patients taking the medication experienced a lower risk of major adverse cardiovascular events, reflected by an adjusted hazard ratio of 0.884, as well as a reduced risk of major adverse kidney events, with an adjusted hazard ratio of 0.775.

Addressing Blind Spots in Medical Literature

Co-author Dr. Bernhard M.W. Schmidt, also from Hannover Medical School, pointed out that very elderly individuals have historically been underrepresented or systematically excluded from large-scale randomized controlled trials due to multimorbidity and frailty. By relying on real-world data, the researchers aimed to address this crucial blind spot in the existing medical literature.

However, experts emphasize that observational findings from real-world datasets require careful interpretation. Because this study relied on matched database records rather than a traditional randomized controlled trial, healthcare providers must weigh potential advantages against individual patient risks. Dr. Schmidt noted that patients in this age group require a careful, individualized risk-benefit assessment and close clinical monitoring when considering new therapeutic regimens.

Understanding Chronic Kidney Disease in Older Populations

• Chronic kidney disease involves the gradual loss of kidney function over time.
• Older adults frequently manage multiple chronic conditions alongside declining renal health.
• Real-world analyses help bridge knowledge gaps where clinical trial data remains limited.

As medical research continues to evolve, findings presented at scientific meetings offer valuable insights into how treatments perform outside of strict clinical trial environments. Patients interested in learning more about chronic kidney disease management or evaluating specific medication risks should consult qualified healthcare professionals for personalized guidance.